Study investigator, Dr. Jeffrey Neul, is featured today on NeurologyLive, discussing trofinetide as a potential treatment for Rett syndrome.
NeurologyLive is a media platform for healthcare professionals treating neurological diseases.Dr. Neul points out that, not only is Lavender the first Phase 3 study that has met primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder.
https://www.neurologylive.com/view/trofinetide-as-an-option-rett-syndrome-treatment
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-20
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.52 |
Change
0.160(1.11%) |
Mkt cap ! $1.811B | |||
| Open | High | Low | Value | Volume |
| $14.49 | $14.61 | $14.32 | $2.626M | 181.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 904 | $15.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.64 | 212 | 2 |
View Market Depth
| Last trade - 15.59pm 15/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |